학술논문
Body mass index may predict the response to ipilimumab in metastatic melanoma: An observational multi-centre study.
Document Type
article
Author
Source
PLoS ONE, Vol 13, Iss 10, p e0204729 (2018)
Subject
Language
English
ISSN
1932-6203
Abstract
INTRODUCTION:Immunotherapy is a well-established treatment option in patients with metastatic melanoma. However, biomarkers that can be used to predict a response in these patients have not yet been found, putting patients at risk of severe side effects. METHODS:In this retrospective analysis, we investigated the association between the body mass index and ipilimumab treatment response in patients with metastatic melanoma. Patients with metastatic melanoma who received a monotherapy of up to 4 doses of ipilimumab (3 mg/kg) every 3 weeks from 2011 to 2014 in three major hospitals in Austria were included. Patients were classified into two groups: normal group (BMI